- Home
- Publications
- Publication Search
- Publication Details
Title
Revisiting Richter transformation in the era of novel CLL agents
Authors
Keywords
Chronic lymphocytic leukaemia, Richter's transformation, Ibrutinib, Venetoclax, TP53, disruption, Genetics
Journal
BLOOD REVIEWS
Volume -, Issue -, Pages 100824
Publisher
Elsevier BV
Online
2021-03-12
DOI
10.1016/j.blre.2021.100824
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Richter’s transformation in patients with chronic lymphocytic leukaemia: a Nationwide Epidemiological Study
- (2020) Yasmin Ben-Dali et al. LEUKEMIA & LYMPHOMA
- A multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH (VR-EPOCH) for Richter’s syndrome.
- (2020) Matthew Steven Davids et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical outcome and prognostic factors of patients with Richter syndrome: real‐world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC)
- (2020) Pau Abrisqueta et al. BRITISH JOURNAL OF HAEMATOLOGY
- Pembrolizumab in relapsed or refractory Richter syndrome
- (2020) Philippe Armand et al. BRITISH JOURNAL OF HAEMATOLOGY
- Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel Agents
- (2020) Lenka Sedlarikova et al. Frontiers in Oncology
- Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study
- (2019) Anas Younes et al. Lancet Haematology
- Risk factors associated with Richter’s transformation in patients with chronic lymphocytic leukaemia: protocol for a retrospective population-based cohort study
- (2019) Mariam Hussein Hleuhel et al. BMJ Open
- Relevance of TP53 for CLL diagnostics
- (2019) Mark A Catherwood et al. JOURNAL OF CLINICAL PATHOLOGY
- Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis
- (2019) Toby A. Eyre et al. BRITISH JOURNAL OF HAEMATOLOGY
- Long-term follow-up of the RESONATE™ phase 3 trial of ibrutinib versus ofatumumab
- (2019) John C. Byrd et al. BLOOD
- Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia
- (2019) Ian W. Flinn et al. BLOOD
- Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis
- (2019) Susan M. O'Brien et al. AMERICAN JOURNAL OF HEMATOLOGY
- Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables
- (2019) Andrew W. Roberts et al. BLOOD
- Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patient in Routine Clinical Practice
- (2019) Lindsey E. Roeker et al. CLINICAL CANCER RESEARCH
- Computed tomography textural analysis for the differentiation of chronic lymphocytic leukemia and diffuse large B cell lymphoma of Richter syndrome
- (2019) C.P. Reinert et al. EUROPEAN RADIOLOGY
- A MULTICENTER, OPEN LABEL, UNCONTROLLED, PHASE II TRIAL EVALUATING SAFETY AND EFFICACY OF VENETOCLAX, ATEZOLIZUMAB ANDOBINUTUZUMAB IN RICHTER TRANSFORMATION FROM CLL
- (2019) M. Montillo et al. HEMATOLOGICAL ONCOLOGY
- PHASE I/II STUDY OF UMBRALISIB (TGR-1202) IN COMBINATION WITH UBLITUXIMAB (TG-1101) AND PEMBROLIZUMAB IN PATIENTS WITH REL/REF CLL AND RICHTER'S TRANSFORMATION
- (2019) A.R. Mato et al. HEMATOLOGICAL ONCOLOGY
- Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
- (2019) Jeff P. Sharman et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece
- (2019) Maria Dimou et al. LEUKEMIA & LYMPHOMA
- State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019
- (2019) Richard Lemal et al. Journal for ImmunoTherapy of Cancer
- Standardization of Sequencing Coverage Depth in NGS: Recommendation for Detection of Clonal and Subclonal Mutations in Cancer Diagnostics
- (2019) Anna Petrackova et al. Frontiers in Oncology
- Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
- (2019) Krish Patel et al. BLOOD
- A CRISPR/Cas9-Generated Murine Model Reveals Cooperation between BCR Signaling and CDKN2A/2B and TP53 Disruption in Richter Syndrome
- (2019) Supriya Chakraborty et al. BLOOD
- PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT)
- (2018) Rong He et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Diagnosis of Richter transformation in chronic lymphocytic leukemia: histology tips the scales
- (2018) Birgit Federmann et al. ANNALS OF HEMATOLOGY
- Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy
- (2018) Steven Coutre et al. BLOOD
- Biology and treatment of Richter syndrome
- (2018) Davide Rossi et al. BLOOD
- Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study
- (2018) Inhye E. Ahn et al. BLOOD
- BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome
- (2018) Andrea Visentin et al. BRITISH JOURNAL OF HAEMATOLOGY
- PD-1 is highly expressed by neoplastic B-cells in Richter transformation
- (2018) Amir Behdad et al. BRITISH JOURNAL OF HAEMATOLOGY
- Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
- (2018) Anthony R. Mato et al. HAEMATOLOGICA
- Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial
- (2018) Stephan Stilgenbauer et al. JOURNAL OF CLINICAL ONCOLOGY
- MYD88 Mutations and Sensitivity to Ibrutinib Therapy
- (2018) Y. Lynn Wang JOURNAL OF MOLECULAR DIAGNOSTICS
- Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial
- (2018) Jeffrey A Jones et al. LANCET ONCOLOGY
- Rapid complete response to blinatumomab as a successful bridge to allogeneic stem cell transplantation in a case of refractory Richter syndrome
- (2018) Juan Pablo Alderuccio et al. LEUKEMIA & LYMPHOMA
- Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
- (2018) John F. Seymour et al. NEW ENGLAND JOURNAL OF MEDICINE
- Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?
- (2018) Benjamin L. Lampson et al. Expert Review of Hematology
- Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
- (2018) Carmen D. Herling et al. Nature Communications
- Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
- (2018) Anthony R. Mato et al. HAEMATOLOGICA
- Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study
- (2018) Xiaojun Huang et al. Cancer Medicine
- NOTCH1 Aberrations in Chronic Lymphocytic Leukemia
- (2018) Emanuela Rosati et al. Frontiers in Oncology
- MiR-125a and MiR-34a expression predicts Richter syndrome in chronic lymphocytic leukemia patients
- (2018) Veronica Balatti et al. BLOOD
- Spatial clonal evolution leading to ibrutinib resistance and disease progression in chronic lymphocytic leukemia
- (2018) Richárd Kiss et al. HAEMATOLOGICA
- Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial
- (2018) Paula Cramer et al. LANCET ONCOLOGY
- Randomized trial of ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia
- (2018) Jan A. Burger et al. BLOOD
- The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
- (2018) Ian W. Flinn et al. BLOOD
- Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation
- (2018) Rashmi Kanagal-Shamanna et al. CANCER
- miRNAs involvement in the pathogenesis of Richter’s syndrome
- (2018) Katrien Van Roosbroeck et al. HAEMATOLOGICA
- Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow-up of the Swedish compassionate use cohort
- (2018) Maria Winqvist et al. HAEMATOLOGICA
- Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
- (2018) Carol Moreno et al. LANCET ONCOLOGY
- Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
- (2018) G. Fraser et al. LEUKEMIA
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
- (2018) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- The 2016 updated WHO classification of lymphoid neoplasias
- (2017) Leticia Quintanilla-Martinez HEMATOLOGICAL ONCOLOGY
- Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib
- (2017) Cameron J. Turtle et al. JOURNAL OF CLINICAL ONCOLOGY
- BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia
- (2017) Jennifer A. Woyach et al. JOURNAL OF CLINICAL ONCOLOGY
- Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
- (2017) Andrew D Zelenetz et al. LANCET ONCOLOGY
- Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
- (2017) John F Seymour et al. LANCET ONCOLOGY
- Common nonmutationalNOTCH1activation in chronic lymphocytic leukemia
- (2017) Giulia Fabbri et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia
- (2017) Paul Yeh et al. Nature Communications
- Histologic transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma
- (2016) Rose Lou Marie C. Agbay et al. AMERICAN JOURNAL OF HEMATOLOGY
- NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome
- (2016) Toby A. Eyre et al. BRITISH JOURNAL OF HAEMATOLOGY
- Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients
- (2016) HAEMATOLOGICA
- Diagnostic dilemmas of high-grade transformation (Richter's syndrome) of chronic lymphocytic leukaemia: results of the phase II National Cancer Research Institute CHOP-OR clinical trial specialist haemato-pathology central review
- (2016) Elizabeth J Soilleux et al. HISTOPATHOLOGY
- Hodgkin lymphoma variant of Richter transformation: morphology, Epstein-Barr virus status, clonality, and survival analysis—with comparison to Hodgkin-like lesion
- (2016) Wenbin Xiao et al. HUMAN PATHOLOGY
- Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study
- (2016) Susan O'Brien et al. LANCET ONCOLOGY
- An 18F-FDG-PET maximum standardized uptake value > 10 represents a novel valid marker for discerning Richter’s Syndrome
- (2016) Anne-Sophie Michallet et al. LEUKEMIA & LYMPHOMA
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Richter syndrome: pathogenesis and management
- (2016) Davide Rossi et al. SEMINARS IN ONCOLOGY
- Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition
- (2016) Jan A. Burger et al. Nature Communications
- Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients
- (2016) HAEMATOLOGICA
- B-Lymphoblastic Leukemia in Patients With Chronic Lymphocytic Leukemia
- (2015) Zaher Chakhachiro et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison tode novoHodgkin lymphoma
- (2015) Sameer A. Parikh et al. AMERICAN JOURNAL OF HEMATOLOGY
- A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia
- (2015) S. M. O'Brien et al. BLOOD
- The efficacy of ibrutinib in the treatment of Richter syndrome
- (2015) M. Tsang et al. BLOOD
- Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
- (2015) P. Jain et al. BLOOD
- Second Cancers and Richter Transformation Are the Leading Causes of Death in Patients With Trisomy 12 Chronic Lymphocytic Leukemia
- (2015) Paolo Strati et al. Clinical Lymphoma Myeloma & Leukemia
- Platinum and high-dose cytarabine-based regimens are efficient in ultra high/high-risk chronic lymphocytic leukemia and Richter's syndrome: results of a French retrospective multicenter study
- (2015) Eric Durot et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- XIV. The pathology of transformation of indolent B cell lymphomas
- (2015) Randy D. Gascoyne HEMATOLOGICAL ONCOLOGY
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
- (2015) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial
- (2015) Mohammed Z H Farooqui et al. LANCET ONCOLOGY
- Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease
- (2015) F R Mauro et al. LEUKEMIA
- Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
- (2015) Wyndham H Wilson et al. NATURE MEDICINE
- Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
- (2015) Kami J. Maddocks et al. JAMA Oncology
- Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation
- (2014) Petra Langerbeins et al. AMERICAN JOURNAL OF HEMATOLOGY
- Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia
- (2014) L. Falchi et al. BLOOD
- Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia
- (2014) D. Rossi et al. BLOOD
- Risk Factors for Richter Syndrome in Chronic Lymphocytic Leukemia
- (2014) Sameer A. Parikh et al. Current Hematologic Malignancy Reports
- Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome
- (2013) E. Chigrinova et al. BLOOD
- Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study
- (2013) C. R. Y. Cruz et al. BLOOD
- Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients
- (2013) Sameer A. Parikh et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Therapy in Aggressive Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome
- (2013) Apostolia M. Tsimberidou et al. Clinical Lymphoma Myeloma & Leukemia
- Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome
- (2013) Giulia Fabbri et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
- (2013) Susan O'Brien et al. LANCET ONCOLOGY
- 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography examination in patients with chronic lymphocytic leukemia may reveal Richter transformation
- (2013) Tomáš Papajík et al. LEUKEMIA & LYMPHOMA
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations
- (2012) J. Edelmann et al. BLOOD
- Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome
- (2012) Davide Rossi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Molecular pathogenesis of chronic lymphocytic leukemia
- (2012) Gianluca Gaidano et al. JOURNAL OF CLINICAL INVESTIGATION
- Autologous and Allogeneic Stem-Cell Transplantation for Transformed Chronic Lymphocytic Leukemia (Richter's Syndrome): A Retrospective Analysis From the Chronic Lymphocytic Leukemia Subcommittee of the Chronic Leukemia Working Party and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
- (2012) Kate Cwynarski et al. JOURNAL OF CLINICAL ONCOLOGY
- Richter transformation in 16 of 149 Chinese patients with chronic lymphocytic leukemia
- (2012) Lei Fan et al. LEUKEMIA & LYMPHOMA
- MGA, a suppressor ofMYC, is recurrently inactivated in high risk chronic lymphocytic leukemia
- (2012) Lorenzo De Paoli et al. LEUKEMIA & LYMPHOMA
- The Notch signalling system: recent insights into the complexity of a conserved pathway
- (2012) K. G. Guruharsha et al. NATURE REVIEWS GENETICS
- NOTCH1 mutations in CLL associated with trisomy 12
- (2011) V. Balatti et al. BLOOD
- The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation
- (2011) D. Rossi et al. BLOOD
- Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature
- (2011) Bruno Bockorny et al. BRITISH JOURNAL OF HAEMATOLOGY
- NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL
- (2011) I. Del Giudice et al. HAEMATOLOGICA
- Mutational Status of theTP53Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial
- (2011) David Gonzalez et al. JOURNAL OF CLINICAL ONCOLOGY
- Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays
- (2011) M Ciccone et al. LEUKEMIA
- Clonally related histiocytic/dendritic cell sarcoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a study of seven cases
- (2011) Haipeng Shao et al. MODERN PATHOLOGY
- Richter transformation in peripheral blood
- (2010) BLOOD
- A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome
- (2010) Silvia Rasi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior
- (2010) E. Gine et al. HAEMATOLOGICA
- TP53Mutation and Survival in Chronic Lymphocytic Leukemia
- (2010) Thorsten Zenz et al. JOURNAL OF CLINICAL ONCOLOGY
- Transformation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma to Interdigitating Dendritic Cell Sarcoma
- (2009) Cory R. Fraser et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- A new genetic lesion in B-CLL: aNOTCH1PEST domain mutation
- (2009) Mauro Di Ianni et al. BRITISH JOURNAL OF HAEMATOLOGY
- The Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism
- (2009) Raphael Kopan et al. CELL
- Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome
- (2009) D. Rossi et al. CLINICAL CANCER RESEARCH
- Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia
- (2009) D Rossi et al. LEUKEMIA
- Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome
- (2008) Davide Rossi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy in Patients With Richter's Syndrome or Fludarabine-Refractory Chronic Lymphocytic Leukemia
- (2008) Apostolia M. Tsimberidou et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started